Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of ...

In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...

Beam Therapeutics, Inc. (($BEAM)) announced an update on their ongoing clinical study. Beam Therapeutics, Inc. is conducting the BEACON trial, ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the SCD ...

Fulcrum Therapeutics (($FULC)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Fulcrum ...

A Phase 1b clinical trial testing pociredir in adults with sickle cell disease has completed enrollment of its high-dose ...

Stroke is a leading cause of death and disability, affecting 1 in 4 people during their lifetime. Stroke happens when blood ...

As President of the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) in Beijing, China, ...

Hinman and Maibach have shown that in human skin wounds, as in pig's skin, epidermal regeneration is faster when the wound surface is moist than when exposed to the air and dry. There is little doubt ...

Everyday Health’s team of board-certified physicians and health professionals contribute to the creation and review of content, ensuring that the information is useful, up to date, and accurate. Susan ...

Incorporating acute ischemic stroke due to large vessel occlusion (LVO) screening using the Los Angeles Motor Scale (LAMS) is ...